BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 09, 2007
 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 7/6 cls
Abraxis (ABBI) Lazard Megan Murphy Rating change Under review (from buy) -2% $21.88
Murphy's change reflects the cancer company's plans to spin out its hospital-based generics business into Abraxis Pharmaceutical Products Inc. (see B5). She is concerned that specifics of the transaction,...

Read the full 369 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >